Abstract：
Endomyocardial biopsy (EMB) is an invasive procedure and a diagnostic tool used mainly on the follow-up of post-heart transplant rejection in the past years. Currently, it has an important role in the diagnosis of non-ischemic cardiomyopathies. EMB is frequently performed through a venous access to enter the right ventricle. Diagnostic performance has improved with advances in pathology analysis. Its complications risk, close to 1% in high-volume interventional centers, can be justified considering the potential benefit of an accurate diagnosis and prognosis.
摘要：
心内膜活检（EMB）是一种侵入性程序，是过去几年主要用于心脏移植后排斥反应随访的诊断工具。目前,在非缺血性心肌病的诊断中具有重要作用。EMB经常通过静脉通路进入右心室。随着病理分析的进步，诊断性能有所提高。其并发症的风险，在高容量介入中心接近1%，考虑到准确诊断和预后的潜在益处，可以证明是合理的。
